Slide 1: Cyclopharm Limited Half Year Presentation
For personal use only Cyclopharm Limited Half Year Presentation August 2007
Slide 2: Highlights
Highlights For personal use only ; Strong balance sheet ; Strong trading cashflow ; First half profit impacted by expensing of investment in Molecular Imaging division and shift in sales product mix ; Development and implementation of Molecular Imaging division on target ; Strong underlying performa
Slide 3: Profit & Loss
Profit & Loss For personal use only For the 6 months ended 30 June 2007 2006 Variance Analysis: PBT $ $ Technegas Division Molecular Imaging establishment costs $0.22 m Revenue 4,790,891 4,357,423 Profit before income tax 603,982 976,165 Non-recurring patent and regulatory applications $0.14 m Molec
Slide 4: Balance Sheet
Balance Sheet For personal use only Balance Sheet Summary 30 June 2007 31 December 2006 Total Current Assets $6.16 m $7.01 m Total Non-current Assets $3.17 m $2.20 m Total Assets $9.33 m $9.21 m Total Current Liabilities $2.91 m $4.42 m Total Non-current Liabilities $0.37 m $5.35 m Total Liabilities
Slide 5: Operating Cashflow
Operating Cashflow For personal use only For the 6 months ended 30 June 2007 2006 Gross receipts from trading $5.75 m $4.40 m Payments to trading partners ($5.26 m) ($3.55 m) Other ($0.25 m) ($0.03 m) Net cashflow from operating activities $0.24 m $0.82 m Additional costs in the period: Molecular Im
Slide 6: Molecular Imaging
Molecular Imaging For personal use only Continued investment in development & establishment of 3 PET Central Pharmacies in Australia Nearing completion of planning, design and site feasibility studies Focus in 2nd half to shift to: Securing locations, construction and fit-out of Pharmacies Obtaining
Slide 7: Technegas Divisional Review
Technegas Divisional Review For personal use only Revenue from TechnegasPlus generators and PAS increased 15% 48 48 units installed in the first half of 2007 underpins future 28 growth of the business through higher PAS sales 19 Regulatory approvals and new marketing authorisations Jun '05 Jun '06 J
Slide 8: Technegas Divisional Review
Technegas Divisional Review For personal use only Revenue Analysis for the 6 months ended 30 June 2007 2006 % Change Sales: TechnegasPlus $1.1 m $0.3 m 267% PAS $3.5 m $3.7 m (5%) Total Technegas sales revenue $4.6 m $4.0 m 15% The launch of TechnegasPlus resulted in a shift of product mix: For the
Slide 9: Outlook
Outlook For personal use only Investment in Molecular Imaging division to accelerate in second half TechnegasPlus generator sales momentum expected to continue Higher PAS sales in 2nd half to improve gross margin Revision of EBIT guidance range for 2007 to $2.4 m - $2.7 m